Around one in ten men with advanced and otherwise untreatable prostate cancer benefit from treatment with the immunotherapy drug pembrolizumab, according to the results of a study published in the Journal of Clinical Oncology (15 June 2018). The trial involved 258 men with prostate cancer who were no longer responding to hormonal or chemotherapy treatment. They received pembrolizumab every 3 weeks for 35 weeks or until progression or intolerable toxicity. Across all patients, the rate of disease control or response lasting six months or more was 11%, including two patients who had a complete response. However, unlike in other tumour types treated with pembrolizumab, PD-L1 status did not predict response.
展开▼
